Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages by Kang, Wen et al.
 
Anti-tat Hutat2:Fc mediated protection against tat-induced
neurotoxicity and HIV-1 replication in human monocyte-derived
macrophages
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Kang, Wen, Wayne A Marasco, Hsin-I Tong, Mary Margaret
Byron, Chengxiang Wu, Yingli Shi, Si Sun, Yongtao Sun, and
Yuanan Lu. 2014. “Anti-tat Hutat2:Fc mediated protection
against tat-induced neurotoxicity and HIV-1 replication in
human monocyte-derived macrophages.” Journal of
Neuroinflammation 11 (1): 195. doi:10.1186/s12974-014-0195-
2. http://dx.doi.org/10.1186/s12974-014-0195-2.
Published Version doi:10.1186/s12974-014-0195-2
Accessed February 17, 2015 8:19:12 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581148
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH Open Access
Anti-tat Hutat2:Fc mediated protection against
tat-induced neurotoxicity and HIV-1 replication in
human monocyte-derived macrophages
Wen Kang
1,2, Wayne A Marasco
3, Hsin-I Tong
2, Mary Margaret Byron
4, Chengxiang Wu
2, Yingli Shi
2, Si Sun
2,
Yongtao Sun
1* and Yuanan Lu
2*
Abstract
Background: HIV-1 Tat is essential for HIV replication and is also a well-known neurotoxic factor causing
HIV-associated neurocognitive disorder (HAND). Currently, combined antiretroviral therapy targeting HIV reverse
transcriptase or protease cannot prevent the production of early viral proteins, especially Tat, once HIV infection has
been established. HIV-infected macrophages and glial cells in the brain still release Tat into the extracellular space
where it can exert direct and indirect neurotoxicity. Therefore, stable production of anti-Tat antibodies in the brain
would neutralize HIV-1 Tat and thus provide an effective approach to protect neurons.
Methods: We constructed a humanized anti-Tat Hutat2:Fc fusion protein with the goal of antagonizing HIV-1 Tat
and delivered the gene into cell lines and primary human monocyte-derived macrophages (hMDM) by an
HIV-based lentiviral vector. The function of the anti-Tat Hutat2:Fc fusion protein and the potential side effects of
lentiviral vector-mediated gene transfer were evaluated in vitro.
Results: Our study demonstrated that HIV-1-based lentiviral vector-mediated gene transduction resulted in a
high-level, stable expression of anti-HIV-1 Tat Hutat2:Fc in human neuronal and monocytic cell lines, as well as in
primary hMDM. Hutat2:Fc was detectable in both cells and supernatants and continued to accumulate to high
levels within the supernatant. Hutat2:Fc protected mouse cortical neurons against HIV-1 Tat86-induced neurotoxicity.
In addition, both secreted Hutat2:Fc and transduced hMDM led to reducing HIV-1BaL viral replication in human
macrophages. Moreover, lentiviral vector-based gene introduction did not result in any significant changes in
cytomorphology and cell viability. Although the expression of IL8, STAT1, and IDO1 genes was up-regulated in
transduced hMDM, such alternation in gene expression did not affect the neuroprotective effect of Hutat2:Fc.
Conclusions: Our study demonstrated that lentivirus-mediated gene transfer could efficiently deliver the Hutat2:Fc
gene into primary hMDM and does not lead to any significant changes in hMDM immune-activation. The neuroprotective
and HIV-1 suppressive effects produced by Hutat2:Fc were comparable to that of a full-length anti-Tat antibody. This
study provides the foundation and insights for future research on the potential use of Hutat2:Fc as a novel gene
therapy approach for HAND through utilizing monocytes/macrophages, which naturally cross the blood-brain barrier,
for gene delivery.
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HIV-associated neurocognitive disorders (HAND) occur
when HIV enters the central nervous system (CNS) and
impairs neuronal function involved in cognitions, includ-
ing memory, learning, attention, problem solving, and
decision making [1]. It can be classified into three cat-
egories, namely asymptomatic neurocognitive impair-
ment, mild neurocognitive disorder, and HIV-associated
dementia [1,2]. Although more severe forms of HAND
are rare thanks to the introduction of combined anti-
retroviral therapy (cART), the prevalence of milder
forms continues to increase [3]. Cross-sectional studies
showed that neurologic disorders occur in half of HIV-
1-infected individuals in the era of cART [3-5]. One ex-
planation for the high prevalence of HAND in the cART
era is that cART cannot completely inhibit HIV replica-
tion in the CNS, which results in persistent HIV replica-
tion at low-levels in the brain [1,6-8]. Either prolonged
toxic inflammatory activation or the presence of toxic
viral products, such as the HIV-1 Tat protein produced
by low-level HIV within the CNS, can continue to drive
neurodegeneration [1,9]. Although several antiretroviral
agents have been found to enter the CNS with higher ef-
ficiency, another issue that arises with cART for HAND
treatment is the lack of a correlation between the CNS
penetration-effectiveness (CPE) index and efficacy of ther-
apy [10]. A recent study has shown that HIV dementia
was even worse among affected individuals who received a
cART regimen with a high CPE score [11]. Therefore, de-
velopment of adjuvant therapies for HAND is urgently
needed.
Gene therapy is currently being explored for combat-
ing HIV-1 infection [12]. There are numerous anti-HIV
gene therapy approaches, all of which can be classified
into three broad categories: genetic vaccine-based strat-
egies utilizing HIV peptides or gene products [13-15];
RNA-based strategies including anti-sense RNA, RNA
decoys (sense RNA), ribozymes, RNA aptamers, mutant
tRNA3
Lys, small interfering RNAs, and microRNAs [16-19];
and protein-based strategies including transdominant
negative proteins, chimeric proteins (fusion proteins),
nucleases, anti-infective cellular proteins, single-chain
variable fragment intrabodies (scFv), and monoclonal anti-
bodies [17,20-23]. Although a combined approach utiliz-
ing both mRNA and protein-based strategies would be
more effective for HAND therapy, each strategy should be
tested independently. It is presently known that vaccine-
based strategies expressing HIV-1 proteins are not suitable
for the treatment of HAND since these proteins are
neurotoxic. Although RNA-based strategies interfere with
intracellular gene expression, they offer no protection
against existing extracellular neurotoxic HIV-1 proteins
and inflammatory cytokines in the CNS. Therefore,
protein-based gene therapy strategies targeting on both
the intra- and extra-cellular neurotoxins would be helpful.
Based on this hypothesis, we have developed a lentiviral
vector-based gene transfer system to deliver the genes of
secretory human brain-derived neurotrophic factor and
soluble tumor necrosis factor-α receptor:Fc fusion protein
into cell lines and primary monocyte-derived macrophages
(MDM). These integrated genes could be expressed with
high efficiency and have been shown to protect against
TNF-α and HIV-1 Tat and gp120-induced neurotoxicity
[24,25]. However, these two candidates are limited in their
ability to inhibit HIV-1 replication directly.
HIV-1 Tat is a conserved non-structural protein that is
essential for HIV-1 replication [26]. It can be secreted by
HIV-1 infected macrophages and glial cells within the
CNS, or easily enter the CNS by crossing the blood-
brain barrier (BBB). Tat functions as a potent neurotoxin
causing HAND directly and indirectly in the brain
[27-30]. For example, Tat injures neurons directly through
the dysregulation of intracellular Ca
2+ levels, increasing
excitotoxicity, and disinhibiting permeable N-methyl-
D-aspartate receptors from Zn
2+-mediated antagonism
[31-33]. In addition, extracellular Tat can cause neuronal
damage indirectly by increasing the expression of nitric
oxide synthase and the release of toxins including nitric
oxide (NO), TNF-α, and IL-1β from monocytes, macro-
phages, glial cells, and brain endothelial cells [28,34-36].
Therefore, any efforts to blunt the Tat effects would be ex-
pected to have profound and significant impact in treating
HIV neuropathogenesis, decreasing the prevalence of
HIV-associated neurological diseases and improving the
quality of life of HIV-infected individuals. Previous at-
tempts utilizing retrovirus-mediated gene transfer of a
humanized anti-Tat intrabody termed as Hutat2 into CD4
+
Tcells have shown to successfully inhibit HIV-1 replication
in infected mammalian cell lines and transduced CD4
+
mononuclear cell populations [37-39]. Furthermore, a re-
cent in vivo study indicated that retrovirus-mediated anti-
Tat scFv Hutat2 transduction increased the relative survival
of transduced CD4
+ T cells infected with chimeric simian
immunodeficiency virus/HIV, and was associated with a
viral load reduction in one rhesus macaque [22].
This study is designed to explore the protective effects
of lentiviral-mediated gene transfer of anti-Tat Hutat2:Fc
against Tat-activated viral transcription as well as Tat-
induced neurotoxicity. We modified the native anti-Tat
Hutat2 sequence and constructed an HIV-1-based lenti-
viral vector HR-Hutat2, which expresses humanized
anti-Tat scFv:Fc fusion protein (Hutat2:Fc) under the
control of the human cytomegalovirus (CMV) promoter.
This vector was shown to transduce human cell lines of
both neuron and monocyte origins, as well as primary
human MDMs (hMDM), resulting in the secretion of
Hutat2:Fc fusion protein, albeit to varying levels. The se-
creted Hutat2:Fc was shown to be protective to mouse
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addition, both secreted Hutat2:Fc and HR-Hutat2-
transduced hMDM led to prevention from Tat-activated
HIV-1 transcription, thus suppressing viral replication
and reducing the spread of viral infection in human
macrophages. Potential adverse effects due to the lenti-
viral vector transduction were also evaluated by asses-
sing the expression profiling of 15 macrophage-related
functional and regulatory genes using a real-time PCR
assay. Our findings lay out the groundwork for future
studies using anti-Tat Hutat2 gene-modified MDM as a
potential therapeutic strategy for HAND.
Methods
Animal care
Balb/c mice were obtained from Dr. Federick Mercier,
University of Hawaii at Manoa, USA. All mice were bred
and maintained in the animal facility of the University of
Hawaii at Manoa following institutional guidelines. All
procedures were reviewed and approved by the Univer-
sity of Hawaii Animal Care and Use Committee and
conducted according to the Animal Welfare Act and Na-
tional Institutes of Health guidelines.
Generation and production of the lentiviral vectors
A transfer plasmid containing an expression cassette for
Hutat2:Fc fusion protein was constructed (Additional
file 1). Briefly, the gene encoding the anti-HIV-1 Tat scFv
Hutat2 with a leader sequence fused to the hinge domain
from the human IgG1 gene and the Fc domain from the
human IgG3 gene was commercially synthesized (GeneArt®,
Life Technologies, Grand Island, NY, USA). The synthetic
gene was amplified by PCR, using primer pairs containing
Xho I and BamH I restriction sites (Additional file 1), and
inserted into the backbone of pHR-HB7-IRES-GFP plas-
mid (generously provided by Dr. V. Planelles, University
of Utah) that was digested with the same enzymes. The
final bicistronic plasmid construct, pHR-Hutat2:Fc-EGFP,
co-expressed the Hutat2:Fc fusion protein under a CMV
promoter and the enhanced green fluorescent protein
(EGFP) via the internal ribosome entry site (IRES) elem-
ent. Another transfer plasmid containing an expression
cassette for anti-Epstein-Barr virus latent membrane pro-
tein 1 scFv (A3H5:Fc) was constructed in the same way
and used as a control. Lentiviral vectors encoding the
Hutat2:Fc (HR-Hutat2)o rc o n t r o l( HR-A3H5) genes were
generated by transient co-transfection in 293 T cells with
pCMV-ΔR8.2 and pCMV-VSV-G. Vector production and
concentration were performed as described previously
[40-42]; 293 T cells were used for vector titration [25].
High-titer lentiviral vector stocks (3.3 to 4.8×10
8 U/mL)
were prepared by sucrose-cushioned ultracentrifugation at
25,000 rpm for 2 hours [40].
Cell lines and culture
Human embryonic kidney 293 T cells (GenHunter Co.,
Nashville, TN, USA) were maintained in Dulbecco’sM o d i -
fied Eagle’s Medium (Corning Life Sciences, Manassas,
VA, USA) supplemented with 1.0 g/L glucose, 4 mM L-
glutamine (Sigma-Aldrich, St. Louis, MO, USA), 1.0 mM
sodium pyruvate (Corning Life Sciences), 100 IU/mL peni-
cillin (Sigma-Aldrich), 0.1 mg/mL streptomycin (Sigma-
Aldrich), 10 mM HEPES (HyClone, South Logan, UT,
USA), and 10% fetal bovine serum (FBS) (HyClone). The
human neuroblastoma cell line HTB-11 (ATCC, Manassas,
VA, USA), was cultured in Minimum Essential Medium
(Eagle) (Corning Life Sciences) supplemented with 2 mM
L-glutamine, 1.0 mM sodium pyruvate, 100 IU/mL peni-
cillin, 0.1 mg/mL streptomycin, and 10% FBS. Culture
media was replaced every 2 to 3 days and cells were sub-
cultured with EDTA solution containing 0.25% trypsin
(Sigma-Aldrich). The human monocytic cell line U937
(ATCC) was cultured in RPMI 1640 (Sigma-Aldrich) sup-
plemented with 2 mM L-glutamine, 1.0 mM sodium pyru-
vate, 100 IU/mL penicillin, 0.1 mg/mL streptomycin, and
10% FBS. Cells were maintained at 37°C in 5% CO2.
Isolation and cultivation of hMDM
Human peripheral blood was anonymously collected from
three blood donors (serum negative for HIV-1, hepatitis B,
and hepatitis C) with specific approval of the University of
Hawaii’s Institutional Review Board (UH IRB). Signed con-
sent forms were received from blood donors and the pro-
cedures for blood collection and usage were reviewed and
approved by the UH IRB. Peripheral blood mononuclear
cells were isolated using Ficoll-Paque™ Plus (GE Health-
care Biosciences, Piscataway, NJ, USA) and plated at a
density of 3.5×10
6 per well in RPMI 1640 medium sup-
plemented with 10% defined FBS (HyClone), 1% sodium
pyruvate, 100 IU/mL penicillin, 0.1 mg/mL streptomycin,
and 1,000 U/mL human macrophage colony stimulating
factor (M-CSF; obtained from 5/9 m α3-18 cell condi-
tioned medium, ATCC#CRL-10154) using 12-well plates,
and incubated at 37°C in 5% CO2. Three days later, non-
adherent cells were removed and fresh medium was re-
placed. A half volume of the culture medium was replaced
every 3 days. The purity of hMDM culture in vitro was
evaluated by staining with a human CD14 monoclonal
antibody conjugated with R-phycoerythrin (Caltag Labora-
tories, CA, USA) as described previously [25].
Primary neuron culture
Primary mouse neurons were isolated from cortices of
early postnatal (P0) Balb/c mice as described previously
[43], except that neurons were plated and maintained
in NeuroCult™ SM1 media (Stemcell™ Technologies,
Vancouver, Canada). In brief, pups were decapitated and
the brain was collected, washed, and placed into the
Kang et al. Journal of Neuroinflammation 2014, 11:195 Page 3 of 21
http://www.jneuroinflammation.com/content/11/1/195dissection media. Meninges and non-cortical forebrain tis-
sues were removed with fine-point forceps. The cortex
was collected and separated into a single-cell suspension
by incubating in 20 U/mL papain solution (Sigma-Aldrich)
for 10 minutes, followed by the addition of 100 U DNase I
(Sigma-Aldrich) and incubation for 5 more minutes, gen-
tle trituration with a fire-polished glass Pasteur pipette,
and filtration through a 0.45-μm cell strainer. Cells were
then resuspended in NeuroCult™ SM1 plating medium
and 1×10
5 cells were plated into wells of a 24-well plate
coated with poly-D-lysine (molecular weight, 30 to 70 K;
Sigma-Aldrich). A half volume of the culture medium was
replaced with fresh NeuroCult™ SM1 maintenance medi-
um every 3 days. Neurons were maintained at 37°C in 5%
CO2 for 6 days before treatments.
Transduction of human cell lines and primary hMDM
HTB-11 cells were transduced with lentiviral vectors and
the transduction efficiency was evaluated following
methods described previously [25]. Briefly, HTB-11 cells
were sub-cultured at a density of 5 ×10
5 in a T25 tissue
culture flask 24 hours before transduction. For transduc-
tion, cell culture medium was removed and cells were
washed twice with Dulbecco’s Phosphate-Buffered Saline
(DPBS) (Corning Life Sciences) followed by addition of
0.5 mL vector stock (multiplicity of infection, MOI = 10)
containing 8 μg/mL polybrene (Sigma-Aldrich), and in-
cubated at 37°C in 5% CO2 for 2 hours. The vector sus-
pension was removed and fresh growth medium was
added. The medium was replaced 24 hours later and
transduction efficiency was evaluated on day 3 post-
transduction. The percentage of GFP
+ cells was deter-
mined by calculating the number of GFP
+ cells and total
cells from randomly selected microscopic fields using an
epi-fluorescence microscope (Nikon Eclipse TE2000-U).
All experiments were performed in triplicate and a total
of 5 random microscopic fields, each containing at least
100 cells, were counted for each test.
U937 cells were transduced using a spin-infection
method. Approximately 1 ×10
5 cells were resuspended
in 100 μL of vector suspension (MOI = 100) in the pres-
ence of 8 μg/mL polybrene (Sigma-Aldrich) and plated
into a 48-well plate. The plate was sealed and spun at
1,500 × g for 90 minutes at 32°C. Cells were washed with
fresh medium and plated into a 12-well plate and cul-
tured at 37°C in 5% CO2. A second-round transduction
was performed the next day. The transduction efficiency
was evaluated on day 8 post-transduction as described
above.
hMDMs cultured in 12-well plates were infected with
HR-Hutat2 vectors at the MOI of 10 or 50 in the pres-
ence of 8 μg/mL polybrene for 1.5 hours on days 7 and
8 in vitro (DIV 7 and DIV 8), respectively. The transduc-
tion efficiency was evaluated on day 8 post-transduction
(DIV 16). All experiments were performed in triplicate.
A total of five random microscopic fields were counted
for each test.
Western blotting
For western blot assay, cells were washed with DPBS three
times, cultured in the serum-free medium, and harvested
2 days later. Cells were lysed with RIPA lysis buffer con-
taining protease inhibitor cocktail (G-Biosiences, St. Louis,
MO, USA). The equal volume of serum-free supernatants
or the equal amount of total proteins in lysates from trans-
duced or non-transduced cells, including HTB-11, U937,
and hMDM cells, were mixed with 5× sodium dodecyl
sulfate (SDS) sample buffer and loaded on 4% stacking/
7.5% separating SDS-polyacrylamide gels (GibcoBRL,
Grand Island, NY, USA). Following electrophoresis at
100 V for 1.5 hours, separated proteins were transferred
onto a nitrocellulose membrane (NCM; GE Hybond ECL,
Pittsburgh, PA, USA). The NMCs were saturated with 1%
bovine serum albumin (BSA; Sigma-Aldrich) in Tris-
buffered saline containing 0.05% Tween 20 (TBST; Sigma-
Aldrich) for 1 hour at room temperature (RT), followed by
incubation with rabbit-anti-human IgG(H+L) (1:1,000 dilu-
tion) (Rockland, Gilbertsville, PA, USA) for 1 hour at RT.
Following extensive washing withTBST, the NCM was in-
cubated with horseradish peroxidase (HRP)-conjugated
goat-anti-rabbit IgG at a dilution of 1:3,000 (Rockland)
at RT for 1 hour, and then washed three more times
with TBST prior to the exposure to a metal enhanced
3,3-diaminobenzidine tetrahydrochloride (DAB) sub-
strate (PIERCE, Rockford, IL, USA) for identification of
protein bands. Equal lane loading was assessed using a
rabbit anti-β-actin antibody at a dilution of 1:1,000
(Rockland).
Enzyme-linked immunosorbent assay (ELISA)
Human IgG ELISA was used to quantify the secreted
Hutat2:Fc in the culture mediums from transduced HTB-
11, U937, and hMDM. A 96-well plate was coated with a
goat-anti-human IgG Fc capture antibody (Rockland)
overnight at 4°C. The plate was then washed three times
with TBST and blocked with TBS containing 1% BSA
(Sigma-Aldrich) for 30 min at RT on an orbital shaker.
After washing three times with TBST, the plate was incu-
bated with diluted Hutat2:Fc containing supernatant
samples for 1 hour and then incubated with a goat anti-
human IgG Fc biotin-conjugated detection antibody
(Rockland) for 1 hour. The plate was then washed and
finally incubated with streptavidin-HRP (Rockland) for
30 min at RT. The presence of Hutat2:Fc protein was de-
tected with tetramethylbenzidine (eBioscience, San Diego,
CA, USA). The enzymatic reaction stopped by adding
50 μL of 1 M sulfuric acid. The optical density values were
read at 450 nm with 570 nm as the reference wavelength
Kang et al. Journal of Neuroinflammation 2014, 11:195 Page 4 of 21
http://www.jneuroinflammation.com/content/11/1/195using a microplate reader (Beckman Coulter AD340,
Fullerton, CA, USA), and compared with a standard curve
of human IgG protein (Sigma-Aldrich, cat# I2511). Finally,
the IgG concentration (CIgG) was transformed to Hutat2:
Fc concentration (CHutat2:Fc) in according to the molecular
weight (MW) ratio of Hutat2:Fc to IgG (CHutat2:Fc=C IgG×
MWHutat2:Fc/MWIgG).
Endogenous IL1β, IL8, IL10, and TNF-α levels in the
supernatants of hMDM and transduced hMDM were
quantified with commercial ELISA kits (human IL1β,
IL10, and TNF-α ELISA Ready-SET-Go! kit, eBioscience;
human IL8 ELISA MAX™ kit, BioLegend, San Diego,
CA, USA) following the manufacturers’ instructions.
Dot-immunobinding assay (DIBA)
NCM strips were equilibrated in TBS and then air-dried;
200 ng of HIV-1 Tat86 (100 μg/mL) (NIH AIDS Reagents
Program, Cat#2222) or Tat dilution buffer were spotted
onto the NCM directly and allowed to air-dry for
30 min. After being blocked with 1% BSA in TBST, the
loaded membranes were incubated with conditioned me-
diums collected from HR-Hutat2 transduced HTB-11,
U937, and hMDM, or from HR-A3H5 transduced HTB-
11 at 4°C overnight. Rabbit-anti-human IgG(H+L) (1:1,000
dilution) (Rockland) and goat anti-rabbit IgG HRP-
conjugated (1:3,000 dilution) (Rockland) were used before
the exposure to a metal enhanced DAB substrate (PIERCE).
Specific binding was visualized by the color deposition on
the NCM. The Tat-loaded membrane incubated with
rabbit anti-Tat serum (1:1,000 dilution) (NIH AIDS Re-
agents Program, Cat#705) followed by the incubation with
HRP-conjugated goat anti-rabbit IgG (1:3,000 dilution)
served as a positive control.
Real-time PCR
Total mRNA was extracted from cell samples using
High Pure RNA Isolation Kit (Roche, Germany) follow-
ing the manufacturer’s instructions. Total RNA concen-
tration was estimated from absorbance at 260 nm
(A260; Beckman Coulter DU 800) and RNA quality was
verified by electrophoresis on ethidium bromide-stained
1.5% agarose gels and by A260/A280 ratios >1.8.
Primers were designed with Primer-BLAST online
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?
LINK_LOC=BlastHome) and/or express Designer™ mod-
ule of express Profiler™ software (Beckman Coulter), and
synthesized from Integrated DNATechnologies (Coralville,
IA, USA). Specific primer pairs were used for the expres-
sion studies as follows: Hutat2: 5′-ACATCTGTGGTTC
TTCCTTCTCCT-3′/5′-TCACTCCATATCACTCCCAG
CCACTC-3′; EGFP: 5′-GGTGAGCAAGGGCGAGGAG-
3′/5′-GCCGGTGGTGCAGATGAACT-3′; ACTB: 5′-AG
GTGACACTATAGAATAGGCATCCTCACCCTGAAG
TA-3′/5′-GTACGACTCACTATAGGGACAGAGGCGT
ACAGGGATAGC-3′. For the gene expression profiling
analysis between transduced and non-transduced hMDM,
in total, 15 primer pairs targeting pro-inflammatory cyto-
kines genes, apoptosis-related genes, tumor-related genes,
and cell signal transduction genes were used (Table 1).
Three reference genes ACTB, GK,a n dEzrin were used for
these normalizations. Primer specificity was confirmed by
capillary gel electrophoresis using GenomeLab™ GeXp
gene analysis system (Beckman Coulter) and melt curve
analysis. When capillary gel electrophoresis was per-
formed, a universal sequence (Forward: 5′-AGGTGAC
ACTATAGAATA-3′; Reverse: 5′-GTACGACTCACTAT
AGGGA-3′) was added to the 5′-end of each forward or
reverse primer following the manufacturer’s instructions.
cDNA was synthesized from 1 μg DNase-treated total
RNA by using a Transcriptor First Strand cDNA Synthesis
Kit (Roche, Germany) according to the manufacturer’s
instructions.
Real-time PCR was performed with i-Cycler iQ5 Real-
time Detection System (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). Each sample was amplified in trip-
licate using 96-well optical plates (Bio-Rad Laboratories
Inc.) in a 20 μL reaction volume using 2 μL cDNA
(10 ng/μL), 10 μL FastStart Universal SYBR Green Mas-
ter (Roche), and 200 nM of the appropriate forward and
reverse primers. Real-time cycling conditions were as
follows: initial denaturation at 95°C for 10 min, followed
by 40 cycles of denaturation at 95°C for 15 sec and an-
nealing at 60°C for 60 sec, and, finally, melt curve ana-
lysis. Template-minus and reverse transcriptase-minus
negative controls were run for each plate and each sample,
respectively. Fold change of gene expression was deter-
mined using the arithmetic comparative method (2
-ΔΔCt).
Three batches of transduced or mock control cells were
tested in all experiments. All real-time PCR tests were
done in triplicates.
Fluorescent immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 10 min
and blocking was performed by incubating for 15 min
with 1% BSA in PBS containing 0.1% Triton X-100
(Sigma-Aldrich). For human IgG Fc staining, cells were
incubated with primary antibody, rabbit anti-human IgG
Fc at a dilution of 1:100, and a secondary antibody goat-
anti-rabbit IgG conjugated with tetraethyl rhodamine
isothiocyanate (TRITC) at a dilution of 1:200 (Rockland
Immunochemical). For mouse neuron staining, cells were
incubated with a rabbit anti-microtubule-associated protein
2 (MAP2) antibody (1:200 dilution) (Millipore, Billerica,
MA, USA), and then incubated with a goat anti-rabbit IgG
TRITC conjugated antibody (1:200 dilution) (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA).
For HIV-1 p24 staining, after fixing and blocking, hMDM
were incubated with an anti-HIV-1 p24 monoclonal
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Cat#530) followed by incubation with goat anti-mouse
IgG conjugated to biotin (1:200 dilution) (Vector labs,
Burlingame, CA, USA), and with streptavidin-TRITC
(1:200 dilution) (Jackson ImmunoResearch Laboratories)
subsequently. For CD14 staining, cells were not fixed and
permeabilized. After three washings with PBS, hMDM
were incubated with a human CD14 monoclonal antibody
conjugated with R-phycoerythrin (1:100 dilution) (Caltag
Laboratories, CA, USA). To stain nuclei, cells were incu-
bated with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich) for 5 min. All the incubations were followed by
extensive washing with PBS. Negative controls consisted
of pre-incubation with 1% BSA in PBS containing 0.1%
Triton X-100 and omission of the primary antibody
followed by corresponding secondary antibody. To de-
tect apoptosis in neurons, a terminal dexoynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
assay using MEBSTAIN Apoptosis TUNEL Kit II (MBL,
Woburn, MA, USA) was performed according to the
manufacturer’s instructions. Immunofluorescent images
were obtained with an inverted epi-microscope (Nikon
Eclipse TE2000-U) using a numerical aperture lens (0.30
or 0.45) and a digital camera attachment. The pictures
were overlaid using ImageJ software (Version 1.48, Na-
tional Institutes of Health, USA).
MTT assay
HTB-11 cells at the exponential growth phase were
seeded into 96-well plates at 1 ×10
4 cells/well in 100 μL
and cultured for 48 hours. Twenty milliliters of MTT so-
lution (5 mg/mL) (Sigma-Aldrich) was added to the
100 μL of medium in each well, and the plate incubated
at 37°C for 4 hours. The solution was removed, followed
by the addition of 100 μL/well of dimethylsulfoxide
(Amresco, Solon, OH, USA) to solubilize the purple for-
mazan crystals produced. Absorbance in each well was
measured at 570 nm using a 96-well plate reader (Beckman
Coulter AD340). To evaluate the neuroprotective effects
of the Hutat2:Fc, HTB-11 cells were treated with HIV-1
Tat86 (500 nM), Tat86, plus the conditioned medium from
HR-Hutat2 transduced HTB-11, U937, or hMDM at a di-
lution of 1:5. Treatment with Tat86 plus anti-Tat antibody
was used as a positive control, while Tat86 plus the condi-
tioned mediums from the HR-A3H5 transduced HTB-11
was used as a negative control. Seventy-two hours later, an
MTTassay was performed as noted above. In some exper-
iments, the vector HR-Hutat2 transduced HTB-11 cells
were treated with HIV-1 Tat86 (500 nM) for 72 hours and
an MTT assay was performed. The vector HR-A3H5-
transduced HTB-11 treated with HIV-1 Tat86 was used as
a negative control. All experiments were performed in
quadruplicate.
Table 1 Primer list for human monocyte-derived macrophage (hMDM)-related functional and regulatory gene expression
analysis
Gene
name
Accession number
[GenBank]
Description Forward sequence (5′→3′) Reverse sequence (5′→3′)
1 IL18 NM_001562 Interleukin 18 TCAGACCTTCCAGATCGCTT TGCCACAAAGTTGATGCAAT
2 FAS NM_000043 Fas cell surface death receptor ACTGTGACCCTTGCACCAAA GCCACCCCAAGTTAGATCTGG
3 EZR* X51521 Ezrin GCCTAGAGGCTGACCGTATG TGTGTATTCTGCAAGCTCCG
4 P53 NM_000546 Tumor protein p53 CTTCGAGATGTTCCGAGAGC TTATGGCGGGAGGTAGACTG
5 TLR1 NM_003263 Toll-like receptor 1 GACTGCCAAATGGAACAGACA AGGGCCTGGTACCCCTATTA
6 GK* NM_203391 Glycerol kinase CTACAATGCTGTGGTGTGGC TCAAGGAGCCAACGAAGTTT
7 IL1β NM_000576 Interleukin 1β CCTCCAGGGACAGGATATGGA CCAGCTGTAGAGTGGGCTTA
8 IL8 NM_000584 Interleukin 8; neutrophil chemotactic factor CACCGGAAGGAACCATCTCA TTGGGGTGGAAAGGTTTGGA
9 IDO1 NM_002164 Indoleamine 2,3-dioxygenase 1 TATTTGTCTGGCTGGAAAGGC GGAGGAACTGAGCAGCATGTC
10 NFKB2 NM_001077494 Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/p100)
AGCAAGAGGCCAAAGAACTG TGCTGTCTTGTCCATTCGAG
11 IFNGR2 NM_005534 Interferon gamma receptor 2 CTGATCTCCGTGGGAACATT TCCTTTGGTGAGCTGTCCTT
12 STAT1 NM_007315 Signal transducer and activator of transcription 1 CTGAGGAGTTTGACGAGGTGT CTATCAACAGGTTGCAGCGAA
13 CCR5 NM_000579 Chemokine (C-C motif) receptor 5 GGGATAGCACTGAGCAAAGC TCTGAAATACGGAGGCTGGT
14 CCL2 NM_002982 Chemokine (C-C motif) ligand 2; monocyte
chemotactic protein-1 (MCP-1)
GCCTCCAGCATGAAAGTCTC AGATCTCCTTGGCCACAATG
15 CASP3 NM_004346 Caspase3, apoptosis-related cysteine peptidase AGCGAATCAATGGACTCTGG AACATCACGCATCAATTCCA
16 ACTB* NM_001101 Beta-actin GGCATCCTCACCCTGAAGTA CAGAGGCGTACAGGGATAGC
17 IL10 NM_000572 Interleukin 10 CGGCGCTGTCATCGATTTCT GTTTCTCAAGGGGCTGGGTC
18 TNF-α NM_000594 Tumor necrosis factor-α CAGAGGGAAGAGTTCCCCAG CCTTGGTCTGGTAGGAGACG
*Reference gene.
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For this experiment, all the tested conditioned mediums
were FBS-free to avoid possible stimulation of astrocyte
growth, and the conditioned mediums from the trans-
duced hMDM on day 9 post-transduction were tested as
representative samples, since the mediums contained the
highest level of Hutat2:Fc as compared to the superna-
tants harvested on the other days. Mouse primary neu-
rons cultured in 24-well plates were treated with HIV-1
Tat86 (500 nM) alone, or Tat adding with the condi-
tioned mediums from HR-Hutat2 transduced hMDM or
HTB-11 (1:5 dilution) on DIV 6 for 3 days. Treatments
with Tat86 plus anti-Tat monoclonal antibody (NIH
AIDS Reagents Program, Cat#7377) was used as a posi-
tive control while Tat86 plus the conditioned mediums
from the HR-A3H5 transduced HTB-11 was used as a
negative control, respectively. Three days later (DIV 9),
cells were fixed with 4% paraformaldehyde and counter-
stained with anti-MAP2 (neuron) followed by TUNEL
(apoptosis) labeling, and DAPI (nuclei) staining as de-
scribed above. Fields were chosen randomly, and at least
five images from five random fields were acquired with
an epi-fluorescence microscope (Nikon Eclipse TE2000-U)
from each of three independent experiments. In normal
neuron culture, there were some TUNEL-positive cells. It
was reported that these represented non-neuronal dividing
cells that were undergoing cell death and apoptotic
neurons from the preparation procedure [43]. Note that
around these structures intact cell bodies were not ob-
served when the images were overlaid together. Therefore,
in this neuron survival evaluation, only the neurons which
had intact cell bodies (red) and nuclei (blue), yet were re-
sistant to TUNEL labeling (green), were calculated as sur-
vivals. The number of surviving neurons and total neuron
numbers were counted manually. The ratio of living neu-
rons in normal neuron culture was arbitrarily defined as
100% neuron survival rate. The relative neuron survival
rate (%) was expressed as a percentage relative to the un-
treated control neurons. Each value is the mean obtained
from five random microscopic fields of three independent
experiments using a 20×objective.
HIV-1 challenge
HIV-1Ba-L strain (R5) was obtained from the NIH AIDS
Reagent Program (Cat#510). Human MDM were iso-
lated and transduced with HR-Hutat2 vectors on DIV 7
and DIV 8. Six-days later, non-transduced hMDM,
transduced hMDM, non-transduced hMDM with anti-
HIV-1 Tat monoclonal antibody (1:100 dilution), or
the conditioned medium from transduced hMDM (1:2
dilution) were incubated with cell-free HIV-1Ba-L (final
concentration of p24 7.8 ng/mL) at 37°C for 2 hours, re-
spectively. Cells were washed three times and fresh
medium was added. Half volumes of the culture
supernatants were collected and replaced with fresh
medium every 3 days for a total of 24 days. Anti-HIV-1
Tat or the conditioned medium from transduced hMDM
were supplemented to the appropriate wells when
medium was replaced. Viral replication was gauged for
p24 levels in the culture supernatants using a commer-
cial HIV-1 p24 ELISA kit (Beckman Coulter) in accord-
ance with the manufacturer’s instructions. The blood
from three donors was used in this test and triple inde-
pendent experiments were performed.
Statistical analysis
Statistical analyses were performed by running the SPSS
Version 16.0 for Windows package. Data were reported
in the text as means ±standard error means (s.e.m). Stu-
dent’s t-test and χ
2 test were used to determine the stat-
istical significance of independent data, appropriately.
One-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison post hoc test was used to
analyze studies with three or more experimental groups.
Comparisons of each group with the control used
Dunnett test. The P values were two-tailed and a P value
less than 0.05 was considered to be significant.
Results
Evaluation of the gene transfer efficiency and the stable
expression of anti-HIV-1 Tat Hutat2:Fc in human neuronal
cell line HTB-11, monocytic cell line U937, and primary
hMDM
The efficiency of lentiviral vector-mediated gene transfer
was evaluated initially in human neuronal and mono-
cytic cell lines. Human neuroblastoma cell line HTB-11
and monocytic cell line U937 were transduced with lenti-
viral vectors HR-Hutat2 at a MOI of 10 and 100, respect-
ively. Under the established experimental conditions,
transduction efficiencies were calculated to be 98.5%±
0.8% for HTB-11 cells and 95.4%±2.5% for U937 cells
(Figure 1A). Furthermore, the expression of the integrated
genes was confirmed by examining transduced HTB-11
for the Fc expression using immunofluorescent staining
with an anti-human IgG Fc specific antibody. EGFP pro-
teins were expressed in both the nuclei and cytoplasm,
whereas Hutat2:Fc was predominately distributed in the
cytoplasm (Figure 1B). HTB-11 cells were also transduced
with control vectors HR-A3H5 containing a construct en-
coding the anti-Epstein-Barr virus latent membrane pro-
tein 1 scFv A3H5 fused to Fc. The transduction efficiency
was as high as that obtained from HR-Hutat2 transduced
HTB-11 cells (data not shown).
Next, we tested whether the vector HR-Hutat2 could
successfully transduce non-dividing primary hMDMs.
The purity of the cultured hMDMs was proved to be
>98% by CD14
+ immunofluorescent staining on DIV 6
(Additional file 2). hMDMs were infected with the
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centrated stock (MOI = 10) on DIV 7 and DIV 8. The
transduction efficiencies were approximately 53.3% and
47.6%, respectively (Figure 1C). There were no signifi-
cant differences in the transduction efficiency between
the two MOI groups (P >0.05).
Furthermore, the transcriptional profiling for the inte-
grated Hutat2 and EGFP genes in transduced HTB-11,
U937, and hMDM were examined by RT-PCR analysis
(Figure 2A) and confirmed by a real-time PCR test. The
expression of Hutat2 and EGFP genes in transduced
cells was normalized with three reference genes (ACTB,
Figure 1 Transduction of human cell lines HTB-11 and U937 as well as primary hMDM by lentiviral vectors HR-Hutat2 expressing
anti-HIV-1 Hutat2:Fc and EGFP. HTB-11 cells (5× 10
5) were transduced in a T25 flask in the presence of 8 μg/mL polybrene for 2 h (multiplicity
of infection, MOI = 10). U937 cells (1×10
5) were transduced twice by spin-infection at 1,500×g for 90 minutes (MOI = 100). Human MDM were
infected with HR-Hutat2 vectors (MOI = 50 or MOI = 10) for 1.5 h on days 7 and 8 in vitro (DIV 7 and DIV 8), respectively. The transduction
efficiencies were evaluated by calculating the percentage of GFP
+ cells from five randomly selected microscopic fields under a fluorescence
microscope on day 3 post-transduction for HTB-11, as well as on day 8 post-transduction for U937 and hMDM, respectively. HTB-11, Non-transduced
HTB-11 cells; HTB-Hutat2, HR-Hutat2 transduced HTB-11 cells; U937, Non-transduced U937 cells; U937-Hutat2, HR-Hutat2 transduced U937 cells; EGFP,
Enhanced green fluorescent protein; hMDM-Hutat2 MOI = 50, HR-Hutat2 transduced hMDM at the MOI of 50; hMDM-Hutat2 MOI = 10, HR-Hutat2
transduced hMDM at the MOI of 10. (A) Expression of EGFP in HR-Hutat2 transduced HTB-11 and U937 cells. (B) Co-location of the Hutat2:Fc and EGFP
expression in HR-Hutat2 transduced HTB-11. Nuclei were counterstained with DAPI (blue). The Hutat2:Fc proteins (red) were expressed in the cytoplasm
while EGFP proteins (green) were expressed both in the nuclei and cytoplasm. (C) Expression of EGFP in transduced hMDM. Fluorescently-labeled cells
were visualized with an epi-microscope (Nikon Eclipse TE2000-U) using a numerical aperture lens (0.30 or 0.45) and a digital camera attachment. The
pictures were overlaid using ImageJ software (Version 1.48, National Institutes of Health, USA). Data represent means±s.e.m. of three independent
experiments. Scale bar = 100 μm.
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The expression levels of the Hutat2 gene in transduced
HTB-11 and transduced U937 were 162.5- and 9.0-fold
higher than that in transduced hMDM, respectively,
while the expression level of the Hutat2 gene in trans-
duced HTB-11 was 18.1-fold higher than that in trans-
duced U937 (Figure 2B). In addition, the expression
levels of EGFP in transduced HTB-11 and U937 cells
were 89.7- and 4.4-fold higher than that determined in
transduced hMDM, respectively (Figure 2C). The dif-
ference in the gene expression between different
transduced cells was further confirmed by an ELISA
quantification of Hutat2:Fc secreted in the supernatants
of transduced HTB-11 and U937 cells. It was shown that
the secretion of Hutat2:Fc in the supernatants of trans-
duced HTB-11 was 17.1-fold higher than that in the su-
pernatants of transduced U937 cells (2.39 ±0.11 μg/10
6
cells/24 h compared with 0.14 ± 0.04 μg/10
6 cells/24 h,
P <0.01) (Figure 2D).
The expression and secretion of Hutat2:Fc in the
transduced HTB-11, U937, and hMDM cells were
confirmed by Western blotting. To assess the production
of Hutat2:Fc extracellularly and intracellularly, cell cul-
ture supernatants containing no FBS and cell lysates
from the above transduced cells were collected or ex-
tracted. Vector-transduced cells expressed Hutat2:Fc
both within cells (cell lysate) and in secreting form (cul-
ture supernatant) (Figure 2E,F). The molecular weight of
Hutat2:Fc fusion protein is approximate 58 kDa.
To quantify the stability of Hutat2:Fc expression and
secretion, transduced HTB-11 and U937 cells were sub-
cultured in vitro for up to 20 passages. The concentra-
tion of Hutat2:Fc in the conditioned medium was
assessed using an ELISA method at every fifth passage.
Our data showed the levels of Hutat2:Fc in the condi-
tioned mediums were stable over the course of 20 cell
passages in HR-Hutat2 transduced cells (Figure 2G).
The percentage of GFP
+ cells in these transduced cell
populations was also found to be stable through the
course of the 20 passages (data not shown). In addition,
the secreted Hutat2:Fc could be accumulated in the con-
ditioned mediums of transduced HTB-11 and U937
Figure 2 Relative gene expression levels of the Hutat2:Fc and EGFP genes in transduced cells and quantification of Hutat2:Fc in
conditioned mediums. (A) Detection of Hutat2 and EGFP mRNA in HR-Hutat2 transduced cells by a RT-PCR qualitative analysis. HTB-Hutat2,
HR-Hutat2 transduced HTB-11 RNA; U937-Hutat2, HR-Hutat2 transduced U937 RNA; hMDM-Hutat2, HR-Hutat2 transduced hMDM RNA; U937,
non-transduced U937 RNA; IC, Internal control RNA from K562 cell line; NTC, No template control; RTase (−), RTase negative control.
(B and C) Quantitative real-time PCR analysis of Hutat2 and EGFP gene expression levels in transduced HTB-11 and U937 cells compared with that
in transduced hMDM (*P <0.01). (D) Comparison of Hutat2:Fc secretion level between transduced HTB-11 and U937 within 24 hours (*P <0.01);
1×10
6 cells were plated into a T-75 flask and the mediums were collected 24 hours later. Hutat2:Fc was quantified by a human IgG ELISA
method. (E and F) Detection of Hutat2:Fc proteins in cell lysate and supernatant of transduced cells by Western blotting. (G) Detection of stable
secretion of Hutat2:Fc in conditioned mediums from HR-Hutat2 transduced HTB-11 (HTB-Hutat2) and U937 cells (U937-Hutat2). Cells were passaged
totally 20 times and an ELISA assay was performed every fifth passage. (H and I) The accumulation of Hutat2:Fc in mediums from transduced HTB-11
and U937 cells; 1×10
6 cells were plated into a T-75 flask and the mediums were collected every 24 hours for 4 days. (J) Kinetics of Hutat2:Fc levels in
cell culture supernatants of transduced hMDM at different MOI after transduction. The levels of secreted Hutat2:Fc were peak on day 9 post-transduction.
The concentrations of Hutat2:Fc were higher at MOI 50 than at MOI 10 in mediums of transduced hMDM at each time point (P <0.01). Results shown
represent mean values from three independent experiments. Error bars denote the s.e.m.
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tration increased exponentially with time and reached to
plateau on day 4 (2.68 ±0.33 μg/mL for HTB-Hutat2
and 126.16 ±10.12 ng/mL for U937-Hutat2).
The levels of secreted Hutat2:Fc in cell culture super-
natants of transduced hMDM were peak on day 9 post-
transduction (DIV 17) in both the MOI 50 group
(213.83±12.03 ng/mL) and MOI 10 group (119.66 ±
13.64 ng/mL), and then gradually fell to 158.06 ±
10.41 ng/mL and 59.45 ± 8.36 ng/ml in these two groups
on day 21 (DIV 29), respectively (Figure 2J). The Hutat2:
Fc secreted into the cell culture mediums could be de-
tected as early as day 3 post-transduction, expressed
much earlier than the expression of EGFP, which became
visibly apparent on day 8 post-transduction. These find-
ings as well as the gene expression profiling indicated
that the expression of genes co-expressed through an
IRES element was weaker than the promoter-proximal
gene(s) [44]. Transduced hMDM were maintained in
good condition for up to 30 days in vitro.
Specific binding of expressed Hutat2:Fc to HIV-1 Tat
After confirming the stable expression of Hutat2:Fc, an
immunoblot assay was employed to assess the specific
binding ability of secreted Hutat2:Fc to HIV-1 Tat. Re-
combinant HIV-1 Tat86 (Clade B) was diluted and blot-
ted onto a NCM with the dilution buffer included as a
blank control. The conditioned medium from HR-A3H5
transduced HTB-11 served as a negative control and
anti-HIV-1 Tat serum served as a positive control. The
conditioned mediums containing anti-HIV-1 Tat Hutat2:
Fc from transduced HTB-11 and U937 cells as well as
hMDM bound specifically to HIV-1 Tat86 while no bind-
ing was detected to neither the blank control nor the
secreted A3H5:Fc control (Figure 3A). In addition, to
confirm that the Hutat2:Fc was able to bind the unag-
gregated form of Tat, Tat86 was separated by SDS-PAGE
electrophoresis and Western blot assay was performed
using the conditioned medium from transduced cells as
primary antibodies. In accordance with the DIBA results,
Hutat2:Fc from HR-Hutat2 transduced cells could spe-
cifically bind to Tat86 (14 kDa), whereas A3H5:Fc from
HR-A3H5 transduced HTB-11 could not (Additional file
3). These tests demonstrate that the secreted Hutat2:Fc
is able to bind specifically and sufficiently to HIV Tat86
as a fully-functional HIV-1 Tat antibody in vitro,a s
designed.
Protection of Hutat2:Fc against HIV-1 Tat-mediated
neurotoxicity
The next important step was to determine whether
binding of anti-HIV-1 Tat Hutat2:Fc to HIV-1 Tat86 can
successfully neutralize the neurotoxic properties of
Tat86. The ability of Hutat2:Fc to antagonize the toxicity
of HIV-1 Tat86 was assessed by using an MTT assay to
determine if the secreted Hutat2:Fc or vector transduc-
tion was able to protect HTB-11 cells against the neuro-
toxic impact of HIV-1 Tat86. When exposed to Tat86
(500 nM), normal HTB-11 cells exhibited a reduced cel-
lular viability (59.4 ±7.8%). Comparatively, HTB-11 cells
Figure 3 Evaluation of the biological binding function of Hutat2:Fc and protective effects of Hutat2:Fc against HIV-1 Tat86-mediated
toxicity in HTB-11 cells. (A) Specific binding of Hutat2:Fc to HIV-1 Tat. HIV-1 Tat86 (Clade B) loaded nitrocellular membranes (NCM) were incubated
with cell culture supernatants collected from HR-Hutat2-transduced HTB-11 (HTB-Hutat2), U937 (U937-Hutat2), or hMDM (hMDM-Hutat2) at 4°C
overnight followed by incubation with rabbit anti-human IgG(H+L) and goat anti-rabbit IgG HRP conjugated antibodies. Specific binding was visualized
by the color deposition on the NCM. The Tat86-loaded membrane incubated with rabbit anti-Tat serum served as a positive control (Pos Ctl) while
incubated with cell culture supernatant from HR-A3H5 transduced HTB-11 served as a negative control (HTB-A3H5). The NCM loaded with Tat dilution
buffer was used as a blank control (BLK Ctl). (B) Functional antagonization of Hutat2:Fc against HIV-1 Tat86-induced toxicity in HTB-11 cells by an MTT
assay. The OD570 value of untreated HTB-11 cells was arbitrarily defined as 100% cell viability. The relative cell viability (%) was expressed as a percentage
relative to the untreated control cells. The cell viability was significantly higher for the cells treated with the conditioned mediums from transduced cells
releasing Hutat:Fc when compared to the cultures that received Tat86 (500 nM) alone (*P <0.01 for HTB-Hutat2 medium;
#P <0.05 for U937-Hutat2
medium, and hMDM-Hutat2 medium). (C) Protection of HR-Hutat2 transduction against Tat86-induced toxicity by an MTT assay. No significant difference
of cell viability was detected between normal and vector HR-Hutat2 transduced HTB-11 cells (HTB-Hutat2) (P >0.05). However, the cell viability of
HTB-11 transduced with the vector HR-Hutat2 was significantly higher than that of HTB-A3H5 in the presence of HIV-1 Tat86 (500 nM) (*P <0.01). All
experiments were performed in quadruplicate. Error bars denote the s.e.m.
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diums from HR-Hutat2 vector-transduced HTB-11,
U937, or hMDM were protected from cellular cytotox-
icity (cell viability was 99.4 ±2.6%, 90.1± 2.8%, and 91.1
±3.1%, respectively; Figure 3B). The slightly lower level
of cyto-protective effects of the conditioned medium
from the transduced hMDM compared to that from the
transduced HTB-11 was due to the lower concentration
of Hutat2:Fc in the conditioned medium. Furthermore,
when exposed to Tat86, HR-Hutat2 transduced HTB-11
cells also showed a dramatically increase in cell viability
of 102.1 ±1.1% in comparison to HR-A3H5-transduced
HTB-11 cells, which only had a viability of 57.5 ±3.8%.
The viability of HR-Hutat2- transduced HTB-11, either
exposed to HIV-1 Tat or not, was comparable to the
normal HTB-11 control (Figure 3C). These data indi-
cated that both HR-Hutat2-transduced HTB-11 itself
and the Hutat2:Fc proteins in the supernatants signifi-
cantly mediated the cytoprotective effects. Taken to-
gether, these data reflect the ability of Hutat2:Fc to
neutralize the biological activity of Tat86.
In addition, these protective effects of Hutat2:Fc in the
conditioned mediums were further evaluated using pri-
mary cultures of mouse neurons. Early postnatal (P0)
Balb/c mouse neurons from cortex were isolated and
cultured for 6 DIVs. The purity of the cultures were
>95% neurons proved by MAP2 and glial fibrillary acidic
protein immunocytochemistry staining (data not shown).
The representative images of normal neurons and neu-
rons treated with Tat86 or Tat86 plus Hutat2:Fc contain-
ing mediums from the transduced hMDM are shown in
Figure 4A. Tat-treated mouse neurons showed increased
numbers of cell apoptosis (Figure 4A TUNEL panel), loss
of dendritic arbor, as well as a shorter dendrite length
(Figure 4A; MAP2 panel). The relative rate of neuron sur-
vival was similar among normal neurons, neurons treated
with Tat86 plus conditioned medium from HTB-Hutat2
(93.0±4.5%), and neurons treated with Tat86 plus anti-Tat
antibody (97.0±7.2%). Compared withTat exposure alone,
the relative rate of neuron survival was increased by 10%,
from 69.3±8.9% to 79.4±7.9% in the presence of con-
ditioned medium from HR-Hutat2-transduced hMDM
(P <0.05). However, the neuron survival rates were not sig-
nificantly changed when adding HTB-A3H5 medium
(66.6±9.6% versus 69.3±8.9%, P >0.05; Figure 4B). These
results indicate that Hutat2:Fc released from transduced
hMDM and HTB-11 could neutralize HIV-1 Tat86-in-
duced neurotoxicity as an anti-Tat antibody in vitro,
whereas A3H5:Fc released from HTB-A3H5 control does
not have that biological effect. In comparison, the protect-
ive level of Hutat2:Fc from the conditioned medium of
transduced hMDM was lower than that obtained from the
use of transduced HTB-11 medium and the commercial
anti-Tat antibody.
Transduced hMDM culture and culture medium resist
challenge with infectious HIV-1
To determine if HR-Hutat2-mediated transduction of
hMDM could inhibit virus infection, both transduced
and normal hMDM control were exposed to full-length
infectious HIV-1Ba-L.
hMDM was transduced with HR-Hutat2 on DIV 7 and
DIV 8 and cultured for 6 days, then normal hMDM, HR-
Hutat2-transduced hMDM, and hMDM supplemented
with anti-HIV-1 Tat or with the conditioned medium from
HR-Hutat2-transduced hMDM were infected with HIV-
1Ba-L, respectively. The level of HIV-1 p24 production
in these cultures was quantified by an ELISA assay
(Figure 5A). HIV-1Ba-L replication (p24 level) was detected
in the control hMDM shortly after virus inoculation (day
3) and gradually increased with post-infection time, reach-
ing the peak level by day 18 post-infection. The level of
viral production dramatically suppressed (by 9- to 16-fold)
in transduced hMDM-Hutat2 and normal hMDM supple-
mented with hMDM-Hutat2-conditioned medium or with
anti-HIV-1 Tat antibody as compared to normal hMDM
cultures (Figure 5A). These results suggest that the lenti-
viral vector-mediated Hutat2:Fc gene transfer conferred a
significant degree of protection against wild-type HIV-1
infection in primary hMDM (P <0.01). In addition, the se-
creted Hutat2:Fc from transduced hMDM can suppress
HIV-1Ba-L propagation as an anti-HIV-1 Tat antibody. In
agreement with this, an HIV-1-induced cytopathic effect
in non-transduced hMDM was evident by the presence of
abnormally large cells, multinucleated cells, and debris
resulting from late stages of cell death. As a comparison,
only very modest levels of HIV-1-induced cytopathic
effects were observed in the transduced cultures or non-
transduced culture supplemented with Hutat2:Fc condi-
tioned medium (Figure 5B). Furthermore, although almost
all of hMDM were infected by HIV-1Ba-L after a 24-day
culture period, the fluorescent signals of p24 staining in
transduced hMDM or in normal hMDM treated with
hMDM-Hutat2 conditioned medium were much weaker
as compared to hMDM control (Figure 5B; p24 panel).
These findings illustrate that although Hutat2:Fc is unable
to completely block the cells from infection by HIV, lenti-
viral vector HR-Hutat2-transduced hMDM (intracellular
Hutat2:Fc) and the Hutat2:Fc secreted from vector-
transduced hMDM (extracellular Hutat2:Fc) are able to
suppress HIV-1 replication and the spread of viral infec-
tion in macrophages.
Potential adverse impacts
A vital component of gene therapy is to ensure that nei-
ther the method of gene delivery nor the subsequent
gene expression causes any adverse effect on the target
cells or tissues. Several experimental tests were conducted
to evaluate the lentiviral vector-mediated transduction of
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cell morphology, proliferation, and cellular activation in
the transcriptional profiling of macrophage-related func-
tional and regulatory genes, and in the releasing of pro-
inflammatory cytokines in transduced hMDM.
First, the comparison of transduced and non-transduced
cells shows no apparent alternation in cell morphology
following the transduction with HR-Hutat2 in both cell
lines and primary hMDM (Figure 1A,C). Transduced cell
lines were monitored for more than 20 passages, and no
change in growth kinetics was observed during that time. In
addition, there were no significant differences in cellular via-
bility between normal HTB-11 and HR-Hutat2-transduced
HTB-11, as determined by an MTTassay (Figure 3C).
Second, a qRT-PCR assay was employed to compara-
tively evaluate the expression of 15 human macrophage-
Figure 4 Protection of the conditioned medium containing Hutat2:Fc against HIV-1 Tat86-mediated neurotoxicity in primary mouse
neurons. Mouse cortical neurons cultured in 24-well plates were treated with HIV-1 Tat86 (Clade B, 500 nM) alone, or Tat with conditioned
mediums from HR-Hutat2-transduced hMDM or HTB-11 (1:5 dilution) on day 6 in vitro (DIV 6) for 3 days. Treatment with Tat plus anti-Tat monoclonal
antibody was used as a positive control, while Tat plus the conditioned medium from HR-A3H5 transduced HTB-11 was used as a negative control,
respectively. (A) Representative images of primary mouse cortical neurons which were treated with HIV-1 Tat86 or Tat86 plus the conditioned medium
from HR-Hutat2-transduced hMDM. Cells were counterstained with anti-MAP2 (MAP2), FITC-dUTP (TUNEL), and DAPI (Nuclei). Images of MAP2, TUNEL,
and Nuclei were merged together (Merge). The survived neurons were the cells which were positive for MAP2 and DAPI but negative for TUNEL
staining. Tat, Neurons treated with HIV-1 Tat86 alone; Tat/hMDM-Hutat2 medium, Neurons treated with HIV-1 Tat86 plus the conditioned medium of
transduced hMDM; Normal control, Untreated neurons. Images were acquired as described in Figure 1. (B) Comparison of relative rates of neuron
survival after treatment. The neuron survival rate of untreated neurons was defined as 100%. The relative neuron survival rate was increased by about
10% by adding Hutat2:Fc containing medium from transduced hMDM (*P <0.05 vs. treatment with Tat alone). However, the rate was still lower than
normal neurons, neurons treated with Tat86 plus HTB-Hutat2 medium, and Tat86 plus anti-Tat antibody (
#P <0.01). Each value is the mean obtained from
five random fields of three independent experiments using a 20× objective. Error bars denote the s.e.m. Scale bar = 100 μm.
Kang et al. Journal of Neuroinflammation 2014, 11:195 Page 12 of 21
http://www.jneuroinflammation.com/content/11/1/195related pro-inflammatory cytokine genes, apoptosis-
related genes, tumor-related genes, cell signal transduc-
tion genes, and cell surface receptor genes (Table 1)
between normal and HR-Hutat2-transduced hMDM on
day 9 post-transduction. Differential gene expression
was considered “significant” when the normalized fold
change of samples versus control was >2 (up-regulated)
or <0.5 (down-regulated). Twelve out of 15 genes
retained their expression at the same level in transduced
hMDM at a MOI of 10 or 50 compared with normal
hMDM (Figure 6A). However, the change of gene ex-
pression level was detected in three genes, IL8, STAT1,
and indoleamine-pyrrole 2,3-dioxygenase (IDO)1. STAT1
was 3.36 ±0.34-fold up-regulated in the MOI 10 group
and 4.29 ±0.77-fold up-regulated in the MOI 50 group
as compared to non-transduced hMDM (P <0.01). It was
326.8±56.5- and 409.3±86.3-fold up-regulated for IDO1
gene expression level in transduced hMDM at a MOI of
Figure 5 Reducing of HIV-1 replication by lentivirus-mediated expression of Hutat2:Fc in primary hMDM. (A) Kinetics of HIV-1Ba−L replications
(HIV-1 p24 levels). The data showed a significant reduction of HIV-1 replication in both the TD-hMDM and Hutat2:Fc culture groups as compared to
hMDM (P <0.01), but no statistical difference among TD-hMDM, Hutat2:Fc, and Anti-Tat groups (P >0.05). (B) Lentiviral vectors HR-Hutat2 transduction
suppresses HIV-1 cytopathicity and the expression of p24 in hMDM cultures. Normal hMDM and HR-Hutat2 transduced hMDM were exposed to
HIV-1Ba-L, and examined before and on day 24 post-viral infection using a 10× objective. It can be readily appreciated that either HR-Hutat2 transduction
or Hutat2:Fc strongly suppressed HIV-1-mediated cytopathic effects, resulting in a reduction in the number of giant cells in the culture. In addition,
HIV-1 p24 immunofluorescent staining showed that HR-Hutat2 transduction and Hutat2:Fc reduced the expression of HIV-1 p24 intracellularly. Images
were acquired as described in Figure 1. hMDM, Normal hMDM; TD-hMDM, HR-Hutat2 transduced hMDM; Anti-Tat, Non-transduced hMDM treated with
anti-HIV-1 Tat antibody; Hutat2,Fc, Normal hMDM treated with conditioned medium from HR-Hutat2 transduced hMDM; D24 post-infection, Day 24
post-HIV-1-infection; p24, HIV-1 p24 immunofluorescent staining; White arrow, HIV-1-induced cytopathic effect. The blood of three donors was usedi n
this assay. Results represent mean values from triple independent experiments and error bars denote the s.e.m. Scale bar = 100 μm.
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creased by 5.2±1.2-fold for the transduction at a MOI of
50 (P <0.01) as compared to non-transduced hMDM.
Furthermore, to confirm whether the differential gene
expression would relate to the protein translation, we se-
quentially evaluated four pro-inflammatory cytokines,
IL1β, IL8, IL10, and TNF-α levels in the conditioned
medium of transduced and non-transduced hMDM.
Consistently with the results of gene expression profil-
ing, the levels of IL1β and TNF-α in the supernatants of
both transduced hMDM groups did not change signifi-
cantly on each post-transduction day as compared to
non-transduced hMDM (Figure 6B,C). The release of
IL10 in each transduced hMDM decreased about 4-fold
on day 3 post-transduction (51.7 ±3.6 pg/mL in the
MOI 10 group and 54.5 ±11.2 pg/mL in the MOI 50
group, compared to 236.4±33.5 pg/mL in the non-
transduced hMDM group), which returned to normal
levels from day 6 post-transduction and maintained
these normal levels on each following day (Figure 6D).
The IL8 levels in the supernatants were increased on
each of the post-transduction days in the MOI 50 group,
which was consistent with the up-regulated IL8 gene
e x p r e s s i o n .H o w e v e r ,i nt h eM O I1 0g r o u p ,a l t h o u g h
the IL8 gene expression level was slightly down-
r e g u l a t e d ,t h e r ew a sn os i g n i f i c a n tc h a n g ef o rt h es e -
cretion of IL8 in the medium compared to the normal
control (Figure 6E).
Discussion
This study had provided evidence for the anti-Tat
Hutat2:Fc neutralizing strategy to successfully attenuate
HIV-1 Tat-induced neurotoxicity in vitro. Specifically,
we cloned the Hutat2:Fc construct into a lentiviral vec-
tor to transduce human cell lines of both neuron and
monocyte origins, as well as primary hMDM. Then, we
characterized the Hutat2:Fc expression, secretion, and
specificity to recognize HIV-1 Tat86. The Hutat2:Fc fu-
sion protein not only protected neurons from HIV-1
Tat-induced neurotoxicity, but also protected hMDM
against HIV-1Ba-L infection in vitro. These results pro-
vided proof-of-concept evidence for a novel therapeutic
approach against HAND through utilizing hMDM as a
therapeutic gene delivery vehicle following transduction
with an HIV-1-based lentiviral vector that expresses hu-
manized anti-HIV-1 Tat Hutat2:Fc.
Figure 6 The effects of transduction with lentiviral vector HR-Hutat2 on the gene expression of human macrophage-related functional
and regulatory genes and on kinetics of pro-inflammatory cytokines IL1β, IL8, IL10, and TNF-α. Human monocyte-derived macrophages
(hMDM) were differentiated from isolated peripheral blood mononuclear cells in M-CSF-containing medium. On day 7 and day 8 in vitro (DIV 7
and DIV 8), hMDMs were transduced with HR-Hutat2 vector at a MOI of 10 or 50. Total RNA was extracted from non-transduced hMDM (Normal)
and transduced hMDM on day 9 post-transduction. Cell culture mediums were collected every 3 days post-transduction. (A) Comparative analysis
of the transcriptional profiling of 15 hMDM-related functional and regulatory genes by qRT-PCR. Among the 15 genes, only the transcription of
IL8, STAT1, and IDO1 genes changed. (B–E) Sequential changes of IL1β, IL10, IL8, and TNF-α levels in the supernatants of normal and transduced
hMDMs at a MOI of 10 or 50. Normal, Non-transduced hMDM; MOI 10, hMDM transduced with HR-Hutat2 at the MOI of 10; MOI 50, hMDM transduced
with HR-Hutat2 at the MOI of 50. *P <0.01,
#P <0.05 compared with normal. Results shown represent mean values from three independent experiments.
Error bars denote the s.e.m.
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is a general agreement that the pathogenic mechanisms
of HAND are induced by neurotoxic HIV-1 proteins, in-
cluding Tat, and by pro-inflammatory cytokines and che-
mokines, as well as NO produced by HIV-1-infected
macrophages and glial cells [27-29,34-36,45-47]. There-
fore, an ideal therapeutic strategy for HAND is to
maximize inhibition of HIV-1 infection and replication
in the CNS, as well as to reduce the release of pro-
inflammatory products. The current approach for the
treatment of HAND is cART [1,48]. However, cART
cannot completely prevent HIV replication in the CNS,
which is why HIV persists at low-levels in the brain and
continues to drive neurodegeneration [1]. Additionally,
different antiretroviral agents show variable penetration
into the CNS. Although a CPE rank system was formal-
ized in order to improve the efficacy of cART for HAND
[7,48], several studies have suggested CPE is a flawed
metric. A cART regimen with a high CPE score did not
improve neurocognitive performance in individuals with
HAND, but rather increased the risk of HIV dementia
[10,11]. Thus, adjuvant therapies such as neuroprotec-
tive and anti-inflammatory approaches are being ex-
plored [1]. To date, adjuvant therapy for HAND is
facing three major challenges: which targets to choose,
what kinds of reagents to deliver, and how to deliver
therapeutic reagents into the CNS.
In this study, the choice of utilizing a humanized anti-
HIV-1 Tat scFv Hutat2 as a therapeutic candidate was
based on the evidence that Hutat2 had been shown to
be highly effective in inhibiting HIV replication both
in vitro and in vivo [22,37-39]. In terms of pathophysi-
ology, both intracellular and extracellular Tat proteins
play an important role in the development of HAND.
Tat is a potent activator of viral transcription, which
promotes the replication of HIV-1 and the production of
other neurotoxic viral proteins including gp120 from
HIV-1-infected cells [49,50]. Although Tat is normally
processed in the nucleus, it is also secreted from infected
cells to affect neighboring cells by causing direct neuro-
toxicity, bystander glial cell activation, and releasing of
pro-inflammatory cytokines, chemokines, and NO
[28,34-36,51]. HIV-1 Tat proteins from primary virus
isolates are encoded by two exons, which consist of 1 to
86 or 1 to 101 amino acids, respectively [52-54]. The
LAI/Bru strain of HIV-1 (Clade B) encodes a Tat protein
which consists of 1 to 86 amino acids due to a prema-
ture stop codon within the second tat exon [55]. HIV-1
Clade C infections are more prevalent in sub-Saharan
Africa and Asia, whereas HIV-1 Clade B is the predom-
inant subtype in the USA, Canada, Western Europe, and
Australia [56]. In addition, the differences in neurotoxicity
of Tat are clade-specific. Several studies have demon-
strated that recombinant Tat clade C has an attenuated
potential for direct neurotoxicity [57-59] and a decreased
ability to induce indirect neurotoxicity [58,60,61]. In a pre-
vious study, Tat-transgenic mice were used as an animal
model for HAND in which a gene that codes for Tat 1 to
86 amino acids was specifically integrated into astrocytes,
producing brain-specific expression [62,63]. In agreement
with others and our previous work, Tat86 at a concentra-
tion of 500 nM or above induced neuron death [24,64].
Thus, in order to evaluate the protective effect of Hutat2:
Fc, we used 500 nM of Tat86 (Clade B) to produce a dy-
namic range of cytotoxicity.
An HIV-1-based lentiviral vector is an effective gene
transfer system for transducing both dividing and non-
dividing cells such as primary cultures of hMDM pre-
pared from human whole blood. To inactivate both the
intracellular and extracellular Tat, a self-inactivating
HIV-1-based lentiviral vector expressing anti-Tat Hutat2:
Fc with a N-terminal IgG leader sequence was used to
transduce human cell lines and primary hMDM. In the
present study, anti-Tat was produced in the scFv:Fc for-
mat as opposed to scFv or to full-length IgG for gene
transfer for several reasons. First, the Fc domain folds
independently and can improve the solubility and stabil-
ity of the partner molecule both in vitro and in vivo, thus
remarkably increasing the fusion protein half-life, which
prolongs therapeutic activity [65,66]. In addition, the Fc
domain can prolong serum half-life by binding to the
neonatal Fc receptor [67,68]. Second, the Fc domain can
increase the expression and secretion of proteins in
mammalian cells to a high level [69,70]. Third, the Fc re-
gion allows for easy cost-effective quantification by
ELISA which was used in this study and purification by
protein-G/A affinity chromatography [66]. Fourth, the
small size of the scFv:Fc format may allow greater tissue
penetration than a whole IgG [20,71]. The IgG leader in
the construct was used to direct the expression of
Hutat2:Fc to the endoplasmic reticulum, where Hutat2:
Fc can be secreted into cell culture medium more effi-
ciently [22]. As evidenced in this study, the transduction
and expression of Hutat2:Fc in HTB-11, U937, and
hMDM cells led to detectable high levels of protein in
the cell culture medium. In HTB-11 and U937 cells, the
Hutat2:Fc gene was stably expressed for more than 20
passages and sustained at a high level, reaching to
600 ng/mL in HTB-11 and 33 ng/mL in U937 within a
24-hour cultivation time. Moreover, we confirmed the
accumulation of the secreted fusion protein in the cul-
ture mediums from these transduced cell lines. Spin-
infection was reported as an efficient method to improve
the transduction efficiency for cell suspensions [72]. It
was noticed that, although the transduction efficiency of
monocytic U937 cells was increased to more than 95%
after the second-round of spin-infection, the Hutat2:Fc
gene expression and the protein secretion levels were
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11 cells. Among transduced HTB-11 and U937 cell lines
and primary hMDM, the highest Hutat2:Fc transcription
level was found in transduced HTB-11 cells, which is
162.5-fold higher than that in transduced hMDM and
18.0-fold higher than that in transduced U937. Similarly,
the difference of the concentration of Hutat2:Fc in con-
ditioned medium was also confirmed. This could partly
explain why the protection effects of the conditioned
medium from transduced hMDM are not as high as
those from transduced HTB-11 and anti-Tat antibody
in vitro. A potential explanation for this difference in
protein expression levels is that HTB-11 cells may have
a higher integrated copy number of the target gene than
myeloid lineage cells, including U937 cell lines and pri-
mary hMDM. This is consistent with previous observa-
tions that neural cells are more readily transduced by
HIV-1-based vectors than cells of myeloid lineage such
as macrophages and microglia [24,73]. In addition, the
intercellular dNTP level was reported to be vital for
HIV-1 reverse transcription and viral replication [74].
However, the concentration of intercellular dNTP in
non-dividing macrophages was very low compared to
that of dividing cells [75,76]. Thus, the HIV-1-based vec-
tor transduction efficiency and the Hutat2:Fc gene ex-
pression level in primary hMDM were not expected to
be as high as those in HTB-11 and U937 cells. Alterna-
tively, it is possible that there may be other intrinsic dif-
ferences in the ability of different cell types to produce
and secrete Hutat2:Fc.
In terms of delivering therapeutic genes into the CNS,
there are several candidate methods, including direct in-
vasive injection of viral vectors or genetically modified
cells into the cerebrum, which compromise the BBB and
produce a reliable gene expression efficiency [77-79].
However, these are not viable therapeutic approaches for
HAND in human since they are often accompanied with
traumatic brain injuries and repetitive administration
may be required. Non-invasive CNS delivery methods
are more viable. Circulating monocytes and monocyte-
derived macrophages are known to migrate across the
BBB and to enter the CNS under normal physiological
conditions and certain pathological circumstances [80-84].
Moreover, some of these cells can subsequently mature
into long-lived tissue-resident brain macrophages and
microglia [84,85]. Thus, monocytes/MDMs have the po-
tential to deliver therapeutic reagents or genes into the
CNS as “Trojan horses” [86]. Some advantageous attempts
have been made for the treatment of neurodegenerative
diseases including HAND. For example, it was reported
that genetically-modified circulating CD11b
+ cells (largely
monocytes) were used to deliver and express the protease
neprilysin gene into the CNS to arrest amyloid deposition
in an Alzheimer’s disease transgenic murine model [82].
Genetically-modified macrophages were utilized to deliver
glial cell-derived neurotrophic factor for the treatment of
Parkinson’s disease in a murine model [87]. Nanoformu-
lated antiretroviral drugs were also delivered into the brain
by MDMs in a murine model of HAND [80]. Thus, in this
study, we explored a promising therapeutic strategy through
the use of MDMs as a potential gene delivery vehicle.
We demonstrated that lentiviral vector-mediated gene
transfer could be successfully used in hard-to-transduce
monocytic cell lines such as U937 and primary hMDM,
which led to stable expression of Hutat2:Fc fusion pro-
tein. Not only was the expression stable at a high level
over time, but also the secreted Hutat2:Fc from different
transduced cells was shown to be consistently biologic-
ally active. DIBA analysis and Western blotting demon-
strated that the secreted Hutat2:Fc bound directly to
HIV-1 Tat86 as a full-length anti-Tat monoclonal antibody,
whereas the A3H5:Fc control could not. In addition,
Hutat2:Fc expressed from lentiviral vector-transduced
HTB-11 or hMDM (at final concentrations of 536 ng/mL
for HTB-Hutat2 and 42.8 ng/mL for hMDM-Hutat2) con-
ferred significant neuroprotection against neurotoxicity in-
duced by HIV-1 Tat86 in the human neuronal cell line
HTB-11 and primary murine neuron culture. Moreover, it
has been reported that although anti-Tat antibody could
not fully block HIV infection, it could suppress HIV
replication [88-90]. As shown in this study, Hutat2:Fc in
conditioned medium from hMDM-Hutat2 at a final
concentration about 106.9 ng/mL was able to suppress
HIV-1Ba-L replication in primary hMDM. Additionally, HR-
Hutat2-transduced hMDM presented resistance against
viral replication. These findings suggest that delivery of
genetically-modified primary MDM expressing Hutat2:Fc
to the CNS to attenuate neuro-inflammation, suppress
HIV-1 replication, and reduce the spread of viral infection
would be a very promising therapeutic strategy against
HIV-1 Tat-induced neurotoxicity. However, it should be
noticed that the production of Hutat2:Fc in transduced
hMDM was not as high as in transduced neuronal HTB-
11 cells. The production of lower amounts of Hutat2:Fc
protein reduced the neuroprotective effect. Furthermore,
it is unclear how efficiently transduced MDM would get
into the CNS and how many transduced MDM would be
necessary to produce a significant effect on the develop-
ment of neuropathology. Another limitation of this study
is that the HIVchallenge experiment was an acute HIV in-
fection ex vivo. We did not evaluate the effect of Hutat2:
Fc on viral suppression in a chronic HIV infection model,
especially when the virus was already suppressed by anti-
retroviral regimens. Further animal studies will be needed
to explore these issues.
The self-inactivating lentiviral vector-based gene ther-
apy is relatively safe and some vectors are currently be-
ing evaluated in clinical trials [91]. Our findings also
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sult in any measurable alternation in cell viability. How-
ever, MDM, considered as plastic cells, are double-edged
swords for anti-infectious immunity as well as tissue in-
jury and repair. As with T cells, monocytes can be acti-
vated and polarized into either the classically activated
pro-inflammatory (M1) macrophages subtype, or an
anti-inflammatory alternatively activated (M2) subtype
according to their micro-environments [92-94]. Defining
macrophages based on their specific functional activities
is a more appropriate approach [94]. Granulocyte macro-
phage colony stimulating factor (GM-CSF) and M-CSF
are involved in the differentiation of monocytes to macro-
phages [92,93]. Specifically, GM-CSF causes initial differ-
entiation of monocytes towards the M1 macrophage
subtype with a pro-inflammatory cytokine profile (e.g.,
TNF-α,I L 1 β, IL6, IL23), whereas M-CSF treatment pro-
duces an anti-inflammatory cytokine (e.g., IL10, TGF-β)
profile similar to M2 macrophages [92,93]. Our findings
also confirmed that M-CSF stimulated the monocytes
within the peripheral blood mononuclear cell population
differentiation toward an M2-like phenotype with a high
production of IL10 (Figure 6C), which would be more
beneficial to the CNS wound healing. However, this
polarization can be switched to an M1-like phenotype
under the circumstance of acute microbe infection [95].
Thus, we investigated the potential immune-activation
induced by lentiviral vector transduction. Our results indi-
cated that the gene expression level of eight immune-
related genes, including IL1β, IL10, IL18, TNF-α, CCL2,
TLR1, IFGR2,a n dCCR5, and four cell cycle regulator,
apoptosis, and signal transduction-related genes, including
Fas, P53, CASP3,a n dNFKB2, in 15 candidate genes were
not significantly changed following transduction as com-
pared to non-transduced hMDM (Figure 6A). No change
was observed in the concentrations of IL1β and TNF-α
after transduction, which further confirmed the results of
qRT-PCR (Figure 6B,C). Transduction with HR-Hutat2 re-
sulted in a dramatical decrease of IL10 production on day
3 post-transduction (Figure 6D). However, this change re-
covered from day 6 post-transduction and other cytokines
related to M1 polarization state, such as IL1β and TNF-α,
did not significantly change during the following days
(Figure 6B–D). This means that lentiviral transduction in-
duced a transient decrease of IL10 production, but did not
completely switch the polarization of hMDM from the
M2 to M1 phenotype.
However, we also found some atypical M1-skewed
polarization profiles in response to lentiviral transduc-
tion. Notably, three genes, including IL8, STAT1, and
IDO1, were up-regulated in transduced hMDM at a
MOI of 50 (Figure 6A). Although the IL8 mRNA expres-
sion was down-regulated, the release of IL8 did not
change in transduced hMDM at a MOI of 10 (Figure 6E).
IL8 is a pro-inflammatory cytokine, which induces
phagocytosis and chemotaxis in target cells, primarily
neutrophils, and also other granulocytes, causing them
to migrate toward the site of infection. STAT1 is a mem-
ber of the signal transducers and activators of transcrip-
tion family, which up-regulated when macrophage
polarized toward an M1 phenotype [96]. IDO encoded
by IDO1 gene is the rate-limiting enzyme of tryptophan
catabolism through the kynurenine pathway, thus caus-
ing depletion of tryptophan. It has been reported that
IDO1 gene expression was up-regulated and IDO activity
was increased in HIV-1 simian immunodeficiency virus
(SIV)-, and feline immunodeficiency virus-infected T
cells as well as macrophages [97-100]. Moreover, HIV-1
Tat was proved to increase expression of IDO in murine
organotypic hippocampal slice cultures and in human
primary astrocytes [101,102]. IDO activation was related
to the modulation of the immune response and neuro-
pathogenic effects in HIV infection. For example, several
findings suggested that an increase of functional IDO
enzymatic activity is correlated with immunosuppression
by its ability to inhibit lymphocyte proliferation and with
increased production of neurotoxins, such as kynurenine
and quinolinic acid, in the brain [97,103-105]. In SIV-
infected macaques, mRNA expression of cytotoxic T
lymphocytes antigen-4 (CTLA-4) and FoxP3, markers of
regulatory T cells (Treg), as well as IDO, were increased
in the spleens, mesenteric lymph nodes, colons, and je-
juna, and were directly correlated to SIV RNA in the
same tissues [99]. CTLA-4 blockade decreased IDO and
viral RNA expression, and increased the effector func-
tion of both SIV-specific CD4
+ and CD8
+ T cells in
lymph nodes [106]. Inhibition of IDO activity led to en-
hanced generation of HIV-1-specific cytotoxic T lym-
phocytes, leading to elimination of HIV-1-infected
macrophages in the CNS [103]. These data indicated in-
creased IDO expression or activity might favor HIV/SIV
replication and the establishment of viral reservoirs in
lymphoid tissues and in the CNS. However, a few studies
showed inconsistent effects regarding the up-regulated
IDO expression on viral replication. Although IDO tran-
scripts were increased in HIV encephalitis, IDO activa-
tion would likely suppress intracellular viral replication
in astrocytes [107]. IDO function probably dissociated
from protein expression, which would be determined by
the local CNS cytokine and NO microenvironment
[107]. A recent study found that the up-regulation of
IDO1 mRNA expression was likely contributed to
macrophage M1 polarization [93]. Furthermore, M1
polarization of hMDM would restrict HIV-1 replication
in pre- and post-integration steps [108]. Hence, the role
of IDO in HIV-induced inflammation of the CNS was
not completely clear and probably double-edged. In this
study, the HIV-1-based lentiviral vector also induced an
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over, similar gene expression profiling was found in both
HR-Hutat2-transduced hMDM at the different MOIs
and HR-A3H5-transduced hMDM (data not shown).
These findings indicated that the up-regulation of IDO1
gene expression was induced by a vector transduction
process independently, and not due to the presence of
Hutat2:Fc. Although vector transduction promoted the ex-
pression of IDO1 gene and stimulated hMDM polarization
towards atypical M1-skewed polarization profiles, the
functions of IDO and M1-skewed profiles in neuropatho-
genesis and viral remission were microenvironment-
dependent and require further investigation. In addition,
our current study did not observe any significant neuro-
toxicity from the conditioned mediums in the neuron pro-
tection assay. In other words, the neuron protective effects
of Hutat2:Fc probably have overpowered the potential side
effects induced by lentiviral vector transduction.
To conclude, this study provides a preliminarily func-
tional evaluation of anti-HIV-1 Tat Hutat2:Fc and trans-
duced cells against Tat86-induced neurotoxicity and HIV-1
challenge in vitro. Further investigations on in vivo neur-
onal protection and HIV-1 inhibition of transduced mono-
cytes/macrophages for gene delivery into the CNS are
required. On the other hand, the vector transduction in-
duced alternation on the expression of several genes, in-
cluding IL8, STAT1,a n dIDO1, presenting potential
immunological effects on transduced macrophages and
the clearance of virus in the CNS. Thus, examining the
potential side effects of exploring this technology as a
therapeutic strategy in HAND animal models is definitely
essential for future studies.
Conclusions
Our study demonstrated that an HIV-1-based lentiviral
vector could efficiently transfer therapeutic the anti-
HIV-1 Tat Hutat2:Fc gene into human neuronal and
monocytic cell lines as well as primary cultures of
hMDM. Hutat2:Fc can be stably expressed and secreted
from the transgenic cells and can protect neurons
against HIV-1 Tat86-induced neurotoxicity, and suppress
but not fully block HIV-1Ba-L replication in both non-
transduced and transduced hMDM in vitro. Moreover,
lentiviral transduction did not result in any significant
changes in cytomorphology and cell viability. Although
the expression of IL8, STAT1, and IDO1 genes was up-
regulated in transduced hMDM, such alternation in
these gene expression profiles did not affect the neuro-
protective effect of Hutat2:Fc. While much work is still
required to develop a viable approach for application in
patients, these findings provide interesting insights for
utilizing Hutat2:Fc gene-modified monocytes/macro-
phages as a potential novel therapeutic strategy for
HAND.
Additional files
Additional file 1: Schematic map of the HIV-1-based transfer plasmid.
The HIV-1-based lentiviral vector was used to express enhanced green
fluorescent protein (EGFP), with either the therapeutic anti-HIV-1 Tat single
chain fragment intrabody (scFv) Hutat2:Fc fusion protein (HR-Hutat2), or the
control scFv A3H5:Fc fusion protein (HR-A3H5); the fusion proteins used the
human IgG leader to direct the expression to the endoplasmic reticulum
and used the Fc domain to increase stability and to tag protein expression.
LTR, Long terminal repeat; ψ, Packaging signal; SD, Splice donor; SA, Splice
acceptor; CMV, Cytomegalovirus promoter; scFv:Fc, The construct encoding
the anti-Tat Hutat2 fused to Fc or the anti-Epstein-Barr virus latent
membrane protein 1 (LMP-1) A3H5 fused to Fc; Fc, Hinge domain from IgG1
and the Fc domain from human IgG3; IRES, Internal ribosome entry site;
GFP, Green fluorescent protein. Primers used for molecular cloning: forward/
reverse, 5′-CCGCTCGAGCGGGCCGGCCATGGCCCAGGTGCA-3′/5′-
CGCGGATCCGCGTTAAATCATTTACCCGGAGACAGG-3′ (italics indicate the
restriction enzyme cutting site).
Additional file 2: CD14 staining for primary culture of hMDM. After
three washings with PBS, primary culture of hMDM was stained with a
human CD14 monoclonal antibody conjugated with R-phycoerythrin on
day 6 in vitro (DIV 6). The purity of hMDM culture in vitro was calculated
to be >98%.
Additional file 3: Specific binding of Hutat2:Fc from transduced
cells to HIV-1 Tat86 by Western blot assay. HIV-1 Tat86 (14 kDa) was
separated by SDS-PAGE electrophoresis and transferred onto NCM. Each
NCM was incubated with the conditioned mediums from HR-Hutat2-
transduced cells (HTB-Hutat2, U937-Hutat2, and hMDM-Hutat2) at 4°C
overnight followed by incubation with rabbit anti-human IgG(H+L) and
goat anti-rabbit IgG-HRP conjugated antibodies, respectively. Specific
binding was visualized by the color deposition on the NCM when DAB
was added. The Tat-containing NCM incubated with the conditioned
medium from HR-A3H5-transduced HTB-11 served as a negative control
(HTB-A3H5), while the Tat-containing membrane incubated with rabbit
anti-Tat serum served as a positive control (Pos Ctl). The lane loaded with
Tat dilution buffer was used as a blank control (BLK Ctl).
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